Novavax, Inc. (NVAX) Holdings Lifted by JPMorgan Chase & Co.
JPMorgan Chase & Co. boosted its holdings in Novavax, Inc. (NASDAQ:NVAX) by 40.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,196,508 shares of the biopharmaceutical company’s stock after purchasing an additional 1,488,403 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.84% of Novavax worth $5,976,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of NVAX. HighTower Advisors LLC boosted its stake in Novavax by 3.8% in the 1st quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 5,250 shares during the period. American International Group Inc. boosted its position in shares of Novavax by 7.1% during the 1st quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 10,965 shares during the last quarter. KCG Holdings Inc. boosted its position in shares of Novavax by 161.0% during the 1st quarter. KCG Holdings Inc. now owns 178,797 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 110,292 shares during the last quarter. State of Wisconsin Investment Board bought a new position in shares of Novavax during the 2nd quarter valued at approximately $230,000. Finally, Federated Investors Inc. PA bought a new position in shares of Novavax during the 2nd quarter valued at approximately $232,000. Institutional investors and hedge funds own 45.17% of the company’s stock.
Novavax, Inc. (NASDAQ:NVAX) opened at 1.16 on Thursday. The company’s market capitalization is $336.28 million. Novavax, Inc. has a 52-week low of $0.73 and a 52-week high of $2.00. The stock’s 50 day moving average price is $1.11 and its 200-day moving average price is $1.07.
Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.16). The firm had revenue of $6.70 million for the quarter, compared to analyst estimates of $6.15 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The business’s revenue was up 168.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.29) earnings per share. Analysts predict that Novavax, Inc. will post ($0.62) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/novavax-inc-nvax-holdings-lifted-by-jpmorgan-chase-co/1609253.html.
In other news, Director James F. Young sold 175,000 shares of Novavax stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $1.06, for a total value of $185,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 4.00% of the company’s stock.
NVAX has been the subject of a number of research reports. BidaskClub downgraded Novavax from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Zacks Investment Research downgraded Novavax from a “buy” rating to a “hold” rating in a research report on Wednesday, July 26th. Piper Jaffray Companies reiterated a “hold” rating and set a $1.50 target price on shares of Novavax in a research report on Wednesday, July 26th. Chardan Capital reiterated a “neutral” rating and set a $1.50 target price on shares of Novavax in a research report on Thursday, July 27th. Finally, Ladenburg Thalmann Financial Services upgraded Novavax from a “neutral” rating to a “buy” rating and set a $1.60 target price for the company in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company. Novavax has an average rating of “Hold” and an average target price of $3.05.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAX).
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.